EUVIMEDEUVIMED entdecken
Kommentar

Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes

Jennifer Linehan, Josh Gottlieb, Solomon L Woldu, Craig Labbate, Kyle Rose, Wade Sexton, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Alan Nieder, Marc Bjurlin, Mitchell Humphreys und 8 weitere

European Urology Focus · 2023-11 · 9 (6) · 1052-1058

DOI: 10.1016/j.euf.2023.05.012 ↗

Kurz gefasst

Kommentar in der Zeitschrift European Urology Focus, 2023-11. Verfasst von Jennifer Linehan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Providence Specialty Medical Group, Santa Monica, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Kidney Neoplasms, Ureteral Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: UGN-101 can be used for chemoablation of low-grade upper tract urothelial carcinoma (UTUC). The gel can be administered via a retrograde route through a ureteral catheter or an antegrade route via a nephrostomy tube. OBJECTIVE: To report outcomes of UGN-101 by route of administration. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective review of 132 patients from 15 institutions who were treated with UGN-101 for low-grade UTUC via retrograde versus antegrade administration. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Survival outcomes are reported per patient. Treatment, complications, and recurrence outcomes are reported per renal unit. Statistical analysis was performed for primary endpoints of oncological response and ureteral stricture occurrence. RESULTS AND LIMITATIONS: A total of 136 renal units were evaluated, comprising 78 retrograde and 58 antegrade instillations. Median follow-up was 7.4 mo. There were 120 cases (91%) of biopsy-proven low-grade UTUC. Tumors were in the renal pelvis alone in 89 cases (65%), in the ureter alone in 12 cases (9%), and in both in 35 cases (26%). Seventy-six patients (56%) had residual disease before UGN-101 treatment. Chemoablation with UGN-101 was used in 50/78 (64%) retrograde cases and 26/58 (45%) antegrade cases. A complete response according to inspection and cytology was achieved in 31 (48%) retrograde and 30 (60%) antegrade renal units (p = 0.1). Clavien grade 3 ureteral stricture occurred in 21 retrograde cases (32%) and only six (12%) antegrade cases (p < 0.01). Limitations include treatment bias, as patients in the antegrade group were more likely to undergo endoscopic mechanical ablation before UGN-101 instillation. CONCLUSIONS: These preliminary results show a significantly lower rate of stricture occurrence with antegrade administration of UGN-101, with no apparent impact on oncological efficacy. PATIENT SUMMARY: We compared results for two different delivery routes for the drug UGN-101 for treatment of cancer in the upper urinary tract. For the antegrade route, a tube is inserted through the skin into the kidney. For the retrograde route, a catheter is inserted past the bladder into the upper urinary tract. Our results show a lower rate of narrowing of the ureter (the tube draining urine from the kidney into the bladder) using the antegrade route, with no difference in cancer control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsKidney NeoplasmsUreteral NeoplasmsHumansConstriction, PathologicMitomycinKidney Pelvis

Stichwörter der Autor:innen

ChemoablationEndoscopic ablationMitomycinUGN-101Upper tract urothelial carcinoma

Substanzen

Mitomycin

Autor:innen und Institutionen

  • Providence Specialty Medical Group, Santa Monica, CA, USA.
  • University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: jgottlie55@gmail.com.
  • University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Moffitt Cancer Center, Tampa, FL, USA.
  • Indiana University Medical Center, Indianapolis, IN, USA.

Zitieren

APA

Linehan, J., Gottlieb, J., Woldu, S. L., Labbate, C., Rose, K., Sexton, W., Kaimakliotis, H., Jacob, J., Dickstein, R., Nieder, A., Bjurlin, M., Humphreys, M., Ghodoussipor, S., Quek, M., O'Donnell, M., Eisner, B. H., Feldman, A. S., Matin, S. F., Lotan, Y., & Murray, K. S. (2023). Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. European Urology Focus, 9(6), 1052-1058. https://doi.org/10.1016/j.euf.2023.05.012

Vancouver

Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, et al. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. European Urology Focus. 2023;9(6):1052-1058. doi:10.1016/j.euf.2023.05.012

BibTeX
@article{Linehan2023,
  author = {Linehan, Jennifer and Gottlieb, Josh and Woldu, Solomon L and Labbate, Craig and Rose, Kyle and Sexton, Wade and Kaimakliotis, Hristos and Jacob, Joseph and Dickstein, Rian and Nieder, Alan and Bjurlin, Marc and Humphreys, Mitchell and Ghodoussipor, Saum and Quek, Marcus and O'Donnell, Michael and Eisner, Brian H and Feldman, Adam S and Matin, Surena F and Lotan, Yair and Murray, Katie S},
  title = {Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes},
  journal = {European Urology Focus},
  year = {2023},
  volume = {9},
  number = {6},
  pages = {1052--1058},
  doi = {10.1016/j.euf.2023.05.012}
}
Kostenlos starten →